<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02626923</url>
  </required_header>
  <id_info>
    <org_study_id>759-TBC</org_study_id>
    <nct_id>NCT02626923</nct_id>
  </id_info>
  <brief_title>Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive &amp; First Switch Patients</brief_title>
  <official_title>Observational Study of the Safety and Efficacy of Nucleoside Reverse Transcriptase Inhibitor Backbones With Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in Antiretroviral Therapy-Naive Patients and First-Switch Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicholaos C Bellos, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Infectious Disease Clinical Research, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypotension does not occur with Maraviroc at a dose of 600 mg/day
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A qualitative description of orthostatic hypotension in patients receiving once daily
      Maraviroc at 600 mg with Epzicom measured by a validated questionnaire
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hypotension related to once daily Maraviroc dosing</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Blood pressure lowering secondary to Maraviroc 600 mg once daily dosing</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">51</enrollment>
  <condition>Drug-induced Hypotension</condition>
  <arm_group>
    <arm_group_label>Patients on once daily Maraviroc</arm_group_label>
    <description>Maraviroc tablet 600 mg once daily 48 weeks</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        HIV impacted individual on therapy with once daily Maraviroc
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Epzicom Maraviroc once daily dosing

        Exclusion Criteria:

          -  Maraviroc with any other back bone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholaos C Bellos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Southwest Infectious Disease, PA</affiliation>
  </overall_official>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2015</study_first_posted>
  <last_update_submitted>December 9, 2015</last_update_submitted>
  <last_update_submitted_qc>December 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Southwest Infectious Disease Clinical Research, Inc.</investigator_affiliation>
    <investigator_full_name>Nicholaos C Bellos, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

